Genzyme Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Lung Cancer Diagnostic
Will Add to Genzyme's Personalized Medicine Testing Portfolio
17-Jan-2008 -
Genzyme Corp. announced that it has entered into a license agreement with Moffitt Cancer Center to obtain exclusive worldwide diagnostic testing rights to the discovery of the relationship of two proteins to patient response to non-small cell lung cancer (NSCLC) treatment. The expression level of ...
diagnostic tests
Expression
Genzyme
+6